Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control after Failure of Basal-Bolus Therapy (BBT) with Other Basal Insulins (BI) in Patients (Pts) with Type 1 Diabetes (T1DM)
Authors: FRITSCHE ANDREAS , PSCHERER STEFAN , ANDERTEN HELMUT , PEGELOW KATRIN , SEUFERT JOCHEN , PFOHL MARTIN 
Published: June 2018

The prospective observational Toujeo-Neo study investigated effects of switching 397 adult pts with T1DM, uncontrolled on BBT (A1c 7.5-10%) with another BI to Gla-300 in daily clinical practice in Germany. Primary endpoint (EP) was duration of response (fasting plasma glucose (FPG) ≤110 mg/dL or A1c ≤ predefined individual A1c target). Secondary EPs included changes in A1c and FPG, body weight (BW) and insulin doses, hypoglycemia incidence and safety. Here we report on pts with 12 months results available (n=181). Pts baseline characteristics, efficacy and hypoglycemia EPs are shown in Table 1. Main previous BI was insulin glargine 100 U/mL (Gla-100; 35.5%). At 12 months, proportions of pts at FPG target (≤110 mg/dL) were highest in pts previously on insulin detemir (n=38; 44.7%) and NPH insulin (n=27; 36.0%), respectively. Percentages of pts at A1c target were highest in pts previously on NPH insulin (n=27; 30.8%) and Gla-100 (n=62; 27.9%), respectively. Hypoglycemia incidences did not change except for a trend in reduction of nocturnal hypoglycemia by &gt;50%. BW remained stable.

In conclusion, switching the BI in BBT to Gla-300 allowed inadequately controlled T1DM pts to reduce their A1c by 0.48% with a trend to lower nocturnal hypoglycemia, minor BI and moderate prandial insulin dose changes after 12 months follow-up.

Disclosure

A. Fritsche: Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH, Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH. S. Pscherer: Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH. H. Anderten: Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH, Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; Sanofi-Aventis Deutschland GmbH, Merck Sharp & Dohme Corp., Eli Lilly and Company, Boehringer Ingelheim GmbH, Pfizer Inc., AstraZeneca, GlaxoSmithKline plc., Novartis AG, Novo Nordisk A/S, Takeda. K. Pegelow: Employee; Self; Sanofi-Aventis Deutschland GmbH. J. Seufert: Speaker's Bureau; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim GmbH. Research Support; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Boehringer Ingelheim GmbH, GI Dynamics Inc.. Research Support; Self; GI Dynamics Inc., GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Ipsen Biopharmaceuticals, Inc., Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation. Research Support; Self; Novartis Pharmaceuticals Corporation. Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Research Support; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH. Research Support; Self; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Self; Sanofi. Research Support; Self; Ypsomed AG. M. Pfohl: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; Sanofi.